OBJECT: In tumor cells the energy production is shifted from aerobic to anaerobic metabolization of glucose, which makes the cerebral metabolic rate of oxygen consumption (CMRO2) a diagnostic parameter for tissue viability. Direct oxygen-17 ((17)O) MRI during inhalation of (17)O gas allows for a non-invasive determination of the CMRO2. However, the low spatial resolution and the fast transverse relaxation of (17)O lead to partial volume effects that severely bias the quantification of signal intensities. The aim of this work was to determine the CMRO2 in a tumor patient by (17)O MRI in combination with a partial volume correction (PVC) scheme. MATERIALS AND METHODS: Direct (17)O MRI was performed in a glioblastoma patient (F, 51 years) prior to surgery at 7 T. The 'geometric transfer matrix' algorithm for volume of interest based PVC was adapted to (17)O MRI to recover the true signal intensities. We determined the CMRO2 values of gray matter (GM), white matter (WM), cerebrospinal fluid (CSF) and the tumor areas of the contrast enhancing rim (CE), the necrotic center (NE), and the perifocal edema (PE) using a three-phase metabolic model. RESULTS: Large differences in the signal increase during (17)O2 inhalation were obtained ranging from less than 2% in the tumor center up to more than 20% in GM areas. After PVC of the signal time curves, we determined CMRO2 values of 0.67 ± 0.08 μmol/g/min (WM), 3.57 ± 0.67 μmol/g/min (GM), 0.35 ± 0.09 μmol/g/min (CE), and 0.42 ± 0.05 μmol/g/min (PE). In CSF and NE no oxygen uptake (i.e. CMRO2 = 0) was determined from the corrected signals, well in accordance with the underlying physiology in these regions. CONCLUSION: The results show that PVC has a strong effect on the resulting CMRO2 values obtained by (17)O MRI. We found substantial differences-especially in GM tissue-between corrected and non-corrected CMRO2 values. Additionally, we demonstrated the feasibility of CMRO2 assessment in a glioblastoma patient by (17)O MRI.
OBJECT: In tumor cells the energy production is shifted from aerobic to anaerobic metabolization of glucose, which makes the cerebral metabolic rate of oxygen consumption (CMRO2) a diagnostic parameter for tissue viability. Direct oxygen-17 ((17)O) MRI during inhalation of (17)O gas allows for a non-invasive determination of the CMRO2. However, the low spatial resolution and the fast transverse relaxation of (17)O lead to partial volume effects that severely bias the quantification of signal intensities. The aim of this work was to determine the CMRO2 in a tumorpatient by (17)O MRI in combination with a partial volume correction (PVC) scheme. MATERIALS AND METHODS: Direct (17)O MRI was performed in a glioblastomapatient (F, 51 years) prior to surgery at 7 T. The 'geometric transfer matrix' algorithm for volume of interest based PVC was adapted to (17)O MRI to recover the true signal intensities. We determined the CMRO2 values of gray matter (GM), white matter (WM), cerebrospinal fluid (CSF) and the tumor areas of the contrast enhancing rim (CE), the necrotic center (NE), and the perifocal edema (PE) using a three-phase metabolic model. RESULTS: Large differences in the signal increase during (17)O2 inhalation were obtained ranging from less than 2% in the tumor center up to more than 20% in GM areas. After PVC of the signal time curves, we determined CMRO2 values of 0.67 ± 0.08 μmol/g/min (WM), 3.57 ± 0.67 μmol/g/min (GM), 0.35 ± 0.09 μmol/g/min (CE), and 0.42 ± 0.05 μmol/g/min (PE). In CSF and NE no oxygen uptake (i.e. CMRO2 = 0) was determined from the corrected signals, well in accordance with the underlying physiology in these regions. CONCLUSION: The results show that PVC has a strong effect on the resulting CMRO2 values obtained by (17)O MRI. We found substantial differences-especially in GM tissue-between corrected and non-corrected CMRO2 values. Additionally, we demonstrated the feasibility of CMRO2 assessment in a glioblastomapatient by (17)O MRI.
Authors: John A D Aston; Vincent J Cunningham; Marie-Claude Asselin; Alexander Hammers; Alan C Evans; Roger N Gunn Journal: J Cereb Blood Flow Metab Date: 2002-08 Impact factor: 6.200
Authors: Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews Journal: Neuroimage Date: 2004 Impact factor: 6.556
Authors: Mark W Woolrich; Saad Jbabdi; Brian Patenaude; Michael Chappell; Salima Makni; Timothy Behrens; Christian Beckmann; Mark Jenkinson; Stephen M Smith Journal: Neuroimage Date: 2008-11-13 Impact factor: 6.556
Authors: Armin M Nagel; Frederik B Laun; Marc-André Weber; Christian Matthies; Wolfhard Semmler; Lothar R Schad Journal: Magn Reson Med Date: 2009-12 Impact factor: 4.668
Authors: Stefan H Hoffmann; Paul Begovatz; Armin M Nagel; Reiner Umathum; Kai Schommer; Peter Bachert; Michael Bock Journal: Magn Reson Med Date: 2011-03-09 Impact factor: 4.668
Authors: C G Rhodes; R J Wise; J M Gibbs; R S Frackowiak; J Hatazawa; A J Palmer; D G Thomas; T Jones Journal: Ann Neurol Date: 1983-12 Impact factor: 10.422
Authors: Keith Thulborn; Elaine Lui; Jonathan Guntin; Saad Jamil; Ziqi Sun; Theodore C Claiborne; Ian C Atkinson Journal: NMR Biomed Date: 2015-06-09 Impact factor: 4.044
Authors: Sebastian C Niesporek; Reiner Umathum; Thomas M Fiedler; Peter Bachert; Mark E Ladd; Armin M Nagel Journal: MAGMA Date: 2017-05-26 Impact factor: 2.310